252 related articles for article (PubMed ID: 22521242)
1. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.
Lindholm EM; Kristian A; Nalwoga H; Krüger K; Nygård S; Akslen LA; Mælandsmo GM; Engebraaten O
Mol Oncol; 2012 Aug; 6(4):418-27. PubMed ID: 22521242
[TBL] [Abstract][Full Text] [Related]
2. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
[TBL] [Abstract][Full Text] [Related]
3. Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations.
Lindholm EM; Krohn M; Iadevaia S; Kristian A; Mills GB; Mælandsmo GM; Engebraaten O
Clin Cancer Res; 2014 Jan; 20(2):404-12. PubMed ID: 24192926
[TBL] [Abstract][Full Text] [Related]
4. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.
Jahangiri A; De Lay M; Miller LM; Carbonell WS; Hu YL; Lu K; Tom MW; Paquette J; Tokuyasu TA; Tsao S; Marshall R; Perry A; Bjorgan KM; Chaumeil MM; Ronen SM; Bergers G; Aghi MK
Clin Cancer Res; 2013 Apr; 19(7):1773-83. PubMed ID: 23307858
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
Roland CL; Dineen SP; Lynn KD; Sullivan LA; Dellinger MT; Sadegh L; Sullivan JP; Shames DS; Brekken RA
Mol Cancer Ther; 2009 Jul; 8(7):1761-71. PubMed ID: 19567820
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
Broggini-Tenzer A; Sharma A; Nytko KJ; Bender S; Vuong V; Orlowski K; Hug D; O'Reilly T; Pruschy M
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25694444
[TBL] [Abstract][Full Text] [Related]
9. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
Shin SJ; Hwang JW; Ahn JB; Rha SY; Roh JK; Chung HC
Invest New Drugs; 2013 Feb; 31(1):1-13. PubMed ID: 22539090
[TBL] [Abstract][Full Text] [Related]
10. Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts.
Borgan E; Lindholm EM; Moestue S; Mælandsmo GM; Lingjærde OC; Gribbestad IS; Børresen-Dale AL; Engebraaten O; Sørlie T
Mol Oncol; 2013 Feb; 7(1):130-42. PubMed ID: 23142657
[TBL] [Abstract][Full Text] [Related]
11. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI.
Zhu W; Kato Y; Artemov D
PLoS One; 2014; 9(1):e86583. PubMed ID: 24466160
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
14. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
15. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
[TBL] [Abstract][Full Text] [Related]
16. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Cassinelli G; Lanzi C; Tortoreto M; Cominetti D; Petrangolini G; Favini E; Zaffaroni N; Pisano C; Penco S; Vlodavsky I; Zunino F
Biochem Pharmacol; 2013 May; 85(10):1424-32. PubMed ID: 23466421
[TBL] [Abstract][Full Text] [Related]
17. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
Schwarz RE; Awasthi N; Konduri S; Cafasso D; Schwarz MA
Ann Surg Oncol; 2010 May; 17(5):1442-52. PubMed ID: 20041350
[TBL] [Abstract][Full Text] [Related]
18. Reappraising antiangiogenic therapy for breast cancer.
Kerbel RS
Breast; 2011 Oct; 20 Suppl 3(0 3):S56-60. PubMed ID: 22015294
[TBL] [Abstract][Full Text] [Related]
19. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
